Composition for enhancing the efficacy of antibody drugs – Japan Patent No. 7088502

Background

This Japanese patent covers compositions using Aureobasidium pullulans-derived β-glucan for enhancing the efficacy of antibody therapy, protecting formulations that synergize β-glucan with therapeutic antibodies.

Key Findings

AP β-glucan compositions are claimed to enhance antibody therapeutic efficacy, specifically through ADCC augmentation. The patent protects the specific combination approaches and formulations that have demonstrated synergistic anti-tumor activity when AP-glucan is used alongside monoclonal antibody therapeutics.

Relevance to Aureobasidium Beta Glucan Research

Patent protection for antibody therapy enhancement represents a significant pharmaceutical application for AP-glucan. This positions AP β-glucan as a clinical adjuvant for antibody cancer therapy — a potentially transformative application given the growing importance of monoclonal antibody treatments in oncology.